RUCONEST® is indicated for treatment of acute HAE attacks in children ≥2 years with HAE due to C1-INH deficiency2**
95.9% (70/73, N=20) of attacks in children aged 5-14 years were treated with a single dose of RUCONEST®1
Median time to onset of symptom relief was 60 minutes1
Incidence of AEs in patients treated for >1 attack did not increase1
*RUCONEST® has an established safety profile in children with HAE >5 years of age.
**RUCONEST® is licensed for children 2 years and above with limited data available for children aged between 2-5 years.²
AE: adverse event; HAE: hereditary angioedema;
Fast, effective, sustained relief in one dose regardless of attack location or severity5-7
A RUCONEST® vial has a shelf life of 4 years, at room temperature, making it convenient for storing at the hospital2
Established safety profile for adults and children ≥5 years1,2
C1 esterase inhibitor (C1-INH) returned to normal levels* in 94% of patients, regardless of age or weight, with just one dose**3
*The normal range of plasma C1-INH in healthy individuals is between 0.70–1.30 U/mL.⁸
**Dosing of RUCONEST® is weight dependent and one dose is, therefore, based on patient weight as follows; <84 kg: 50 U/kg (1–2 vials); ≥84 kg: fixed dose of 2 vials (4200 U).²
Findings from research conducted with patients and healthcare professionals in the UK and Spain in 2021/20228,9
The patient perspective
208 patients with HAE in the UK and Spain participated in a survey. Patients self-reported answers based on their perceptions and beliefs. The survey excluded patients below 16 years of age.8
Pressure or tightness in skin8
Feeling tired
or fatigued8
Pressure or widespread
abdominal pain8
Mood changes8
Overall, 60% could identify early signs of an acute HAE attack (n=208).8
The HCP perspective
8 HCPs across Europe (Bulgaria, Spain, Italy, Hungary, UK, France, and Netherlands) and Israel were interviewed on HAE and the early signs of an acute HAE attack.9
Early signs and attacks are believed by most healthcare professionals to be a single event9
Early signs do not always result in acute HAE attacks9
Erythema marginatum (EM) is considered a reliable early sign of acute HAE attacks9
Early signs of acute HAE attacks can be difficult to differentiate from other illnesses9
According to the international WAO/EAACI guideline for the management of HAE published in 2022, early treatment is associated with a shorter time to resolution of symptoms and a shorter total attack duration regardless of attack severity. Therefore, it is recommended that HAE attacks should be treated as early as possible.10
Patients can be supported in differentiating early signs from other ‘everyday’ aches and pains. The most frequently reported sites of early signs are:8
Abdominal pain
Swelling in hands or feet
Fatigue
Rash
Tightness of skin, genitals (for males)
Healthcare professionals could discuss early signs of an acute HAE attack with patients to help take appropriate action.
RECOMBINANT
Identical amino acid sequence to native human C1-INH9
FAST
Rapid onset of action6,7
EFFECTIVE
96% of patients experience relief with just one dose5,8
SUSTAINED RELIEF
One dose stops attacks for at least 3 days in 93% of patients4
RUCONEST® is indicated for treatment of acute angioedema attacks in adults, adolescents, and children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency.
References